Pfizer-BioNTech COVID-19 Shot Elicits Strong Antibody Response In Elderly Patients, Study Suggests.

April 1, 2021

Bloomberg (4/1, Gillespie) reports the Pfizer-BioNTech COVID-19 vaccine “generated strong antibody responses in 98% of elderly people in a U.K. study” assessing patients aged 80 to 96. These patients also were “able to mount a defense against the Brazil variant after two injections, although it was less robust, according to the research conducted by the University of Birmingham.” Researchers additionally found “that participants who had previously been infected with the coronavirus experienced a strong antibody response after just one injection.” The findings were published as a pre-print in the Lancet.

        Reuters (4/1) also reports.

Last modified on 04/02/2021

Back to Top